NZSG Executive are Hard at Work

Posted Friday April 8, 2022

The Executive Committee and many dedicated NZSG members have progressed many projects these past two months. We've shared a few in this panui.

Here are some other key pieces of work: 

  • In conjunction with NZAGS we have given extensive written feedback to Te Whatu Ora after earlier hui.
  • We have progressed with a Sustainability working group
  • The Society's inaugural Strategic Plan has been finalised, and will be sent to members under a separate correspondence
  • The Executive and R-EXIT committee continue to manage all the complexities of major organisational change
  • Applications for Match 2022 have closed and work is underway in the selection process. April-Mae has done a power of work ‘back of house’ to streamline the Match process
  • Our Equity working group continue to progress their important mahi
  • An IBD Medication Action Group, led by Dr Estella Johns is hard at work to communicate with Pharmac and work out how NZSG can strategically approach current and future applications
  • The annual reporting for 2022 has begun and we will be reaching out to members for reporting at our ASM
  • I attended the Budget 2022 announcement by Hon Peeni Henare on investment in our Māori and Pacific health workforce and have reached out for further information on applying for funding.
Image by: NZ Gastro Office

That's just a small snippet of what the Executive has been doing since our June edition and hope you enjoy the August Panui. 


Related Articles

2025 Advanced Gastroenterology Training Opportunities (Match 2024) Information

Tuesday April 2, 2024

NZSG will be accepting applications for placements from the 8th of April 2024. The final date for applying is Friday the...

Vacancies Events + 2 More

Read more »

NZCCRTGE - Conjoint Committee News

Friday March 15, 2024

The NZCCRTGE has made a few changes we'd like to let you know about


Read more »

Supply Issue Notice from Pharmac

Thursday February 15, 2024

We've received news about long-term supply issue affecting the Dipentum brand of olsalazine (250 mg capsules and 500 mg ...

News Pharma News

Read more »